Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries.
Company profile
Ticker
VIVE
Exchange
Website
CEO
Scott C. Durbin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • GigCapital5 • Outset Medical ...
Former names
PLC SYSTEMS INC
SEC CIK
Corporate docs
IRS number
43153858
VIVE stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
6 Feb 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
RW
Registration withdrawal request
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
Transcripts
VIVE
Earnings call transcript
2022 Q3
11 Nov 22
VIVE
Earnings call transcript
2022 Q2
11 Aug 22
VIVE
Earnings call transcript
2022 Q1
13 May 22
VIVE
Earnings call transcript
2021 Q4
17 Mar 22
VIVE
Earnings call transcript
2021 Q3
12 Nov 21
VIVE
Earnings call transcript
2021 Q2
13 Aug 21
VIVE
Earnings call transcript
2021 Q1
14 May 21
VIVE
Earnings call transcript
2020 Q4
19 Mar 21
VIVE
Earnings call transcript
2020 Q3
12 Nov 20
VIVE
Earnings call transcript
2020 Q2
13 Aug 20
Latest ownership filings
4
Steven L Basta
5 Jan 23
4
Scott Durbin
5 Jan 23
4
DEBORA JORN
5 Jan 23
4
Arlene Morris
5 Jan 23
4
Sharon Collins Presnell
5 Jan 23
4
Jim B Robbins
5 Jan 23
SC 13G/A
Hudson Bay Capital Management LP
4 Feb 22
SC 13G/A
Empery Asset Management, LP
18 Jan 22
4
DEBORA JORN
6 Jan 22
4
Arlene Morris
6 Jan 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 5.91 mm | 5.91 mm | 5.91 mm | 5.91 mm | 5.91 mm | 5.91 mm |
| Cash burn (monthly) | 1.17 mm | 1.40 mm | 1.55 mm | 1.76 mm | 1.12 mm | 1.35 mm |
| Cash used (since last report) | 9.53 mm | 11.32 mm | 12.60 mm | 14.29 mm | 9.06 mm | 10.97 mm |
| Cash remaining | -3.62 mm | -5.42 mm | -6.69 mm | -8.38 mm | -3.15 mm | -5.06 mm |
| Runway (months of cash) | -3.1 | -3.9 | -4.3 | -4.8 | -2.8 | -3.7 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 32 |
| Opened positions | 6 |
| Closed positions | 8 |
| Increased positions | 6 |
| Reduced positions | 7 |
| 13F shares | Current |
|---|---|
| Total value | 13.74 bn |
| Total shares | 12.42 mm |
| Total puts | 1.10 k |
| Total calls | 41.50 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Opaleye Management | 4.59 mm | $6.84 bn |
| Ikarian Capital | 2.77 mm | $4.12 bn |
| aaronson wayne | 1.78 mm | $0.00 |
| Linden Capital | 921.60 k | $2.55 mm |
| Vanguard | 591.02 k | $880.62 mm |
| Linden Advisors | 454.92 k | $677.83 mm |
| BLK Blackrock | 307.95 k | $458.85 mm |
| Boothbay Fund Management | 258.84 k | $385.68 mm |
| Geode Capital Management | 155.83 k | $232.00 k |
| Renaissance Technologies | 135.05 k | $201.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jan 23 | Jim B Robbins | RSU Common Stock | Grant | Acquire A | No | No | 0 | 57,000 | 0.00 | 57,000 |
| 3 Jan 23 | Morris Arlene | RSU Common Stock | Grant | Acquire A | No | No | 0 | 36,000 | 0.00 | 36,000 |
| 3 Jan 23 | Sharon Collins Presnell | RSU Common Stock | Grant | Acquire A | No | No | 0 | 36,000 | 0.00 | 36,000 |
| 3 Jan 23 | Basta Steven L | RSU Common Stock | Grant | Acquire A | No | No | 0 | 72,000 | 0.00 | 72,000 |
| 3 Jan 23 | Debora Jorn | RSU Common Stock | Grant | Acquire A | No | No | 0 | 36,000 | 0.00 | 36,000 |